Fig. 6: β-Catenin inhibitors inhibit PSG expression and PCa xenograft growth in mice.
a,b IC50 values of PCa cell lines treated with ICG-001 (a) or PRI-724 (b). c,d RT-qPCR (c) and Western blot (d) analysis of expression of indicated mRNAs and proteins in VCaP cells treated with vehicle or different doses of ICG-001. e MTS assay in VCaP cells treated with vehicle or different doses of ICG-001. f,g RT-qPCR (f) and Western blot (g) analysis of expression of indicated mRNAs and proteins in VCaP cells treated with vehicle or different doses of PRI-724. h MTS assay in VCaP cells treated with vehicle or different doses of PRI-724. i–k Representative images of VCaP xenograft tumors harvested after 23 days of ICG-001 treatment (i), tumor growth curve (j) and weight of tumors at day 23 of treatment (k). l Representative IHC images of indicated proteins in tumors as shown in (i). m Quantitative data of IHC intensity of each protein. n.s., not significant. Data in (a, b, c), and (f) were shown as means ± s.d. from three independent experiments. The western blot assays in (d) and (g) were repeated two independent times with similar results. Data in (e) and (h) were shown as means ± s.d. from five replicates. Data in (j) and (k) were shown as means ± s.d. from five xenografts. Data in (m) was shown as means ± s.d. from three independent experiments. For each experiment, five independent fields were enrolled for the calculation. Two-tailed Student’s t test was performed in (a, b, c, f, k) and (m). Two-way ANOVA was performed in (e, h) and (j).
